Antipsychotic drugs (APDs), olanzapine and clozapine, do not effectively address the cognitive symptoms of schizophrenia and can cause serious metabolic side-effects. Liraglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with anti-obesity and neuroprotective properties.
The aim of this study was to examine whether liraglutide prevents weight gain/hyperglycaemia side-effects and cognitive deficits when co-administered from the commencement of olanzapine and clozapine treatment.
Methods:
Rats were administered olanzapine (2 mg/kg, three times daily (t.i.d.)), clozapine (12 mg/kg, t.i.d.), liraglutide (0.2 mg/kg, twice daily (b.i.d.)), olanzapine + liraglutide co-treatment, clozapine + liraglutide co-treatment or vehicle (Control) (n = 12/group, 6 weeks). Recognition and working memory were examined using Novel Object Recognition (NOR) and T-Maze tests. Body weight, food intake, adiposity, locomotor activity and glucose tolerance were examined.
Results:
Liraglutide co-treatment prevented olanzapine- and clozapine-induced reductions in the NOR test discrimination ratio (p < 0.001). Olanzapine, but not clozapine, reduced correct entries in the T-Maze test (p < 0.05 versus Control) while liraglutide prevented this deficit. Liraglutide reduced olanzapine-induced weight gain and adiposity. Olanzapine significantly decreased voluntary locomotor activity and liraglutide co-treatment partially reversed this effect. Liraglutide improved clozapine-induced glucose intolerance.
Conclusion:
Liraglutide co-treatment improved aspects of cognition, prevented obesity side-effects of olanzapine, and the hyperglycaemia caused by clozapine, when administered from the start of APD treatment. The results demonstrate a potential treatment for individuals at a high risk of experiencing adverse effects of APDs.
AbbasTFaivreEHolscherC (2009) Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer’s disease. Behav Brain Res205: 265–271.
2.
Abdul-MonimZReynoldsGPNeillJC (2006) The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res169: 263–273.
3.
AddyNLevinED (2002) Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. Neuropsychopharmacology27: 534–541.
4.
AlbaughVLHenryCRBelloNTet al. (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring)14: 36–51.
5.
AlbaughVLJudsonJGShePet al. (2010) Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry16: 569–581.
6.
AlhadeffALRupprechtLEHayesMR (2012) GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology153: 647–658.
7.
AlvarezEMartínezMDRonceroIet al. (2005) The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem92: 798–806.
8.
AnderbergRHAneforsCBergquistFet al. (2014) Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior. Physiol Behav136: 135–144.
9.
AravagiriMTeperYMarderSR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos20: 369–377.
10.
ArchieSWilsonJOsborneSet al. (2003) Pilot study: Access to fitness facility and exercise levels in olanzapine-treated patients. Can J Psychiatry48: 628–632.
11.
BaldessariniRJCentorrinoFFloodJGet al. (1993) Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology9: 117–124.
12.
BarrAMWuCHWongCet al. (2013) Effects of chronic exercise and treatment with the antipsychotic drug olanzapine on hippocampal volume in adult female rats. Neuroscience255: 147–157.
13.
BassilFFernagutPOBezardEet al. (2014) Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?Prog Neurobiol118: 1–18.
14.
BeebeLHSmithKBurkRet al. (2011) Effect of a motivational intervention on exercise behavior in persons with schizophrenia spectrum disorders. Community Ment Health J47: 628–636.
15.
BevinsRABesheerJ (2006) Object recognition in rats and mice: A one-trial non-matching-to-sample learning task to study ‘recognition memory’. Nat Protoc1: 1306–1311.
16.
BombaMCiavardelliDSilvestriEet al. (2013) Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death Dis4: e612.
17.
BoydaHNTseLProcyshynRMet al. (2010) A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuro-Psychopharmacol Biol Psychiatry34: 945–954.
18.
CastroCCDos Reis-LunardelliEASchmidtWJet al. (2007) Clozapine and olanzapine but not risperidone impair the pre-frontal striatal system in relation to egocentric spatial orientation in a Y-maze. Curr Neurovasc Res4: 235–239.
19.
ChenSLiuARAnFMet al. (2012) Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer’s disease by exendin-4. Age (Dordr)34: 1211–1224.
20.
ChengDLowJKLoggeWet al. (2014) Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice. Psychopharmacology (Berl)231: 3009–3017.
21.
ChoiSDiSilvioBUnangstJet al. (2007) Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci81: 1024–1030.
22.
CooperGDHarroldJAHalfordJCet al. (2008) Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: Implications for animal models of antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry32: 428–436.
23.
DasCMendezGJagasiaSet al. (2012) Second-generation antipsychotic use in schizophrenia and associated weight gain: A critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry24: 225–239.
24.
DavoodiNKalinichevMKorneevSet al. (2009) Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology203: 693–702.
25.
de WitHMVervoortGMJansenHJet al. (2014) Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: A 26 week, randomised clinical trial (ELEGANT). Diabetologia57: 1812–1819.
26.
DeaconRMJRawlinsJNP (2006) T-maze alternation in the rodent. Nat Protoc1: 7–12.
27.
DuringMJCaoLZuzgaDSet al. (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med9: 1173–1179.
28.
El BekayRCoín-AragüezLFernández-GarcíaDet al. (2016) Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes. Br J Pharmacol173: 1820–1834.
29.
FengPYuDMChenLMet al. (2015) Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Acta Pharmacol Sin36: 200–208.
30.
FreudenbergFMarxVSeeburgPHet al. (2013) Circuit mechanisms of GluA1-dependent spatial working memory. Hippocampus23: 1359–1366.
31.
FujiiTOkudaJTsukiuraTet al. (2002) The role of the basal forebrain in episodic memory retrieval: A positron emission tomography study. Neuroimage15: 501–508.
32.
GarberAHenryRRRatnerRet al.; LEAD-3 (Mono) Study Group (2011) Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab13: 348–356.
33.
HäggSJoelssonLMjörndalTet al. (1998) Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry59: 294–299.
34.
HamiltonAHolscherC (2009) Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport20: 1161–1166.
35.
HanMHuangXFChenDCet al. (2013) Diabetes and cognitive deficits in chronic schizophrenia: A case-control study. PLoS One8: e66299.
36.
HolscherC (2013) Central effects of GLP-1: New opportunities for treatments of neurodegenerative diseases. J Endocrinol221: T31–T41.
37.
HolstJJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev87: 1409–1439.
38.
HolstJJBurcelinRNathansonE (2011) Neuroprotective properties of GLP-1: Theoretical and practical applications. Curr Med Res Opin27: 547–558.
39.
HunterKHolscherC (2012) Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci13: 33.
40.
IshøyPLFagerlundBBrobergBVet al. (2017a) No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. Acta Psychiatr Scand136: 52–62.
41.
IshøyPLKnopFKBrobergBVet al. (2014) Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist: Protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study—The TAO study protocol. BMJ Open4: e004158.
42.
IshøyPLKnopFKBrobergBVet al. (2017b) Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial. Diabetes Obes Metab19: 162–171.
43.
IshøyPLKnopFKVilsbøllTet al. (2013) Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. Am J Psychiatry170: 681–682.
44.
KahnRSKeefeRS (2013) Schizophrenia is a cognitive illness: Time for a change in focus. JAMA Psychiatry70: 1107–1112.
45.
KameiHNagaiTNakanoHet al. (2006) Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Biol Psychiatry59: 75–84.
46.
KarasawaJHashimotoKChakiS (2008) D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res186: 78–83.
47.
KasperSResingerE (2003) Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology28(Suppl 1): 27–38.
48.
KastinAJAkerstromV (2003) Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord27: 313–318.
49.
KatsuradaKYadaT (2016) Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist. J Diabetes Investig7(Suppl 1): 64–69.
50.
KeedySKReillyJLBishopJRet al. (2015) Impact of antipsychotic treatment on attention and motor learning systems in first-episode schizophrenia. Schizophr Bull41: 355–365.
51.
KeefeREBilderRMDavisSMet al. (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry64: 633–647.
52.
KilkennyCBrowneWJCuthillICet al. (2010) Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol8: e1000412.
53.
LarsenJRVedtofteLJakobsenMLet al. (2017) Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: A randomized clinical trial. JAMA Psychiatry74: 719–728.
LeeJParkS (2005) Working memory impairments in schizophrenia: A meta-analysis. J Abnorm Psychol114: 599–611.
56.
LepageMBodnarMBowieCR (2014) Neurocognition: Clinical and functional outcomes in schizophrenia. Can J Psychiatry59: 5–12.
57.
LeuchtSCorvesCArbterDet al. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet373: 31–41.
58.
LevinEDChristopherNC (2006) Effects of clozapine on memory function in the rat neonatal hippocampal lesion model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry30: 223–229.
59.
LevinEDPetroABeattyA (2005) Olanzapine interactions with nicotine and mecamylamine in rats: Effects on memory function. Neurotoxicol Teratol27: 459–464.
60.
LindMHirschIBTuomilehtoJet al. (2015) Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: Randomised clinical trial (MDI Liraglutide trial). BMJ351: h5364.
61.
LindenmayerJPKhanAKaushikSet al. (2012) Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr Res142: 171–176.
62.
LykkegaardKLarsenPJVrangNet al. (2008) The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res103: 94–103.
63.
McCleanPLHölscherC (2014) Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology76(Pt A): 57–67.
McCleanPLParthsarathyVFaivreEet al. (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci31: 6587–6594.
66.
McCormickPNKapurSGraff-GuerreroAet al. (2010) The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. Neuropsychopharmacology35: 1826–1835.
67.
McGuireKABlahnikMMSponheimSR (2013) Discrimination within recognition memory in schizophrenia. Behav Sci3: 273–297.
68.
McGurkSRLeeMAJayathilakeKet al. (2004) Cognitive effects of olanzapine treatment in schizophrenia. MedGenMed6: 27.
69.
MerchenthalerILaneMShughrueP (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol403: 261–280.
70.
MutluOUlakGCelikyurtIKet al. (2011) Effects of olanzapine and clozapine on memory acquisition, consolidation and retrieval in mice using the elevated plus maze test. Neurosci Lett501: 143–147.
71.
NHMRC (2013) Australian Code for the Care and Use of Animals for Scientific Purposes, 8th edn.Canberra: NHMRC.
72.
NielsenRELevanderSKjaersdam TelleusGet al. (2015) Second-generation antipsychotic effect on cognition in patients with schizophrenia: A meta-analysis of randomized clinical trials. Acta Psychiatr Scand131: 185–196.
73.
Ortega-AlvaroAGibert-RaholaJMicóJA (2006) Influence of chronic treatment with olanzapine, clozapine and scopolamine on performance of a learned 8-arm radial maze task in rats. Prog Neuropsychopharmacol Biol Psychiatry30: 104–111.
74.
OsborneALSolowijNBabicIet al. (2017) Improved social interaction, recognition and working memory with cannabidiol treatment in a prenatal infection (poly I:C) rat model. Neuropsychopharmacology42: 1447–1457.
75.
PelletierMAchimAMMontoyaAet al. (2005) Cognitive and clinical moderators of recognition memory in schizophrenia: A meta-analysis. Schizophr Res74: 233–252.
76.
PerryTHaugheyNJMattsonMPet al. (2002) Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther302: 881–888.
77.
Pi-SunyerXAstrupAFujiokaKet al. (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med373: 11–22.
78.
PorterDWKerrBDFlattPRet al. (2010) Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes Metab12: 891–899.
79.
PouzetBMowTKreilgårdMet al. (2003) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav75: 133–140.
80.
PurvesRD (1992) Optimum numerical integration methods for estimation of area-under-the-curve (AUC) and area-under-the-moment-curve (AUMC). J Pharmacokinet Biopharm20: 211–226.
81.
Ramos-MiguelAHonerWGBoydaHNet al. (2015) Exercise prevents downregulation of hippocampal presynaptic proteins following olanzapine-elicited metabolic dysregulation in rats: Distinct roles of inhibitory and excitatory terminals. Neuroscience301: 298–311.
82.
Reagan-ShawSNihalMAhmadN (2008) Dose translation from animal to human studies revisited. FASEB J22: 659–661.
83.
ReichenbergAWeiserMCaspiAet al. (2006) Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. J Clin Exp Neuropsychol28: 193–207.
84.
ReillyJLHarrisMSHKhineTTet al. (2007) Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia. Biol Psychiatry62: 818–821.
85.
RichardJEAnderbergRHGötesonAet al. (2015) Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system. PLoS One10: e0119034.
86.
RobinsonLEHoltTAReesKet al. (2013) Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis. BMJ Open3: e001986.
87.
SharmaAShettyMParidaAet al. (2014) Effect of ethanolic extract of Acacia auriculiformis leaves on learning and memory in rats. Pharmacognosy Res6: 246–250.
88.
SmithGChaussadeCVickersMet al. (2008) Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia51: 2309–2317.
89.
StahlSMMignonLMeyerJM (2009) Which comes first: Atypical antipsychotic treatment or cardiometabolic risk?Acta Psychiatr Scand119: 171–179.
90.
SteinertREBeglingerCLanghansW (2016) Intestinal GLP-1 and satiation: From man to rodents and back. Int J Obes40: 198–205.
91.
SturisJGotfredsenCFRomerJet al. (2003) GLP-1 derivative liraglutide in rats with beta-cell deficiencies: Influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol140: 123–132.
92.
TamuraKMinamiKKudoMet al. (2015) Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic mice. PLoS One10: e0126003.
93.
TulipanoGRizzettiCBianchiIet al. (2007) Clozapine-induced alteration of glucose homeostasis in the rat: The contribution of hypothalamic-pituitary-adrenal axis activation. Neuroendocrinology85: 61–70.
94.
van CanJSlothBJensenCBet al. (2014) Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond)38: 784–793.
95.
Weston-GreenKHuangXFDengC (2011) Olanzapine treatment and metabolic dysfunction: A dose response study in female Sprague Dawley rats. Behav Brain Res217: 337–346.
96.
Weston-GreenKHuangXFDengC (2013) Second generation antipsychotic-induced type 2 diabetes: A role for the muscarinic M3 receptor. CNS Drugs27: 1069–1080.
97.
Weston-GreenKHuangXFLianJet al. (2012) Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol22: 364–373.
98.
WoodwardNDPurdonSEMeltzerHYet al. (2007) A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects. Schizophr Res89: 211–224.
